1393352-90-3

Basic information

• Product Name: (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine
• Synonyms: (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine
• CAS NO: 1393352-90-3
• Molecular Weight: 347.46
• Mol File: 1393352-90-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine(1393352-90-3)
• EPA Substance Registry System: (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine(1393352-90-3)

Safety Data

• Hazardous Substances Data: 1393352-90-3(Hazardous Substances Data)

Upstream product

• 1022151-47-8 3-bromoquinolin-6-yl acetate 
• 24306-33-0 methyl quinolin-6-ylethanoate 
• 13669-57-3 3-bromo-6-hydroxyquinoline 
• 580-16-5 6-hydroxyquinoline 
• 1337882-50-4 6-(benzyloxy)-3-bromoquinoline 
• 100-39-0 benzyl bromide 

Relevant articles and documents

6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: Formula (I) wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).